[Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies].

Background: Topical measures are still the mainstay in the therapy of mild-to-moderate acne vulgaris. Azelaic acid 20% in a cream formulation has been established as an efficacious and safe topical drug for 15 years. A new non-alcoholic hydrogel formulation containing 15% azelaic acid was clinically tested against two standard drugs--5% benzoyl peroxide (BPO) and 1% clindamycin.

Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne.

Background/aims: The primary aim of the study was to establish the clinical efficacy and safety of a combined treatment consisting of topical 20% azelaic acid (AA) cream and the oral antibiotic minocycline in the therapy of severe inflammatory acne (nodular papulopustular acne and acne conglobata) in a comparison with oral isotretinoin therapy. The secondary aim was to establish the value of AA cream as maintenance therapy in the prevention of recurrent acne.

Methods: This open-label but randomised study involved 85 patients with nodular papulopustular acne or acne conglobata (Leeds grading scale > 4) who were treated for 6 months.

Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports.

Azelaic acid cream (20 percent) is a new topical treatment for acne with an additional therapeutic potential in rosacea and hyperpigmentation disorders. Azelaic acid (AzA; HOOC-(CH2)7-COOH) is a naturally occurring compound that interferes with acne pathogenesis by virtue of its antikeratinizing, antibacterial, and anti-inflammatory properties. Vehicle-controlled studies have verified that AzA exercises a significant and clinically relevant effect on both non-inflammatory and inflammatory acne lesions.

[Possible side effect of hormonal contraception: porphyria cutanea tarda].

The increased incidence of cases with porphyria cutanea tarda (p.c.T.

[Porphyria cutanea tarda or praematura as a symptom of the hepatotoxicity of hormonal contraception].

It is reported on an evident increase in female patients with porphyria cutanea tarda, seen in dermatological department of Halle/S. since 1975. Our female patients were much younger than patients with p.

[Dacarbazin -- therapy of metastazising malignant melanoma (author's transl)].

Surgery has continuously improved the prognosis of malignant melanoma but not in case of metastases. Widespread metastases are only accessible to palliative chemotherapy. This paper deals with therapy by Dacarbazin in 19 patients suffering from metastazising malignant melanoma.